Target intelligence / Profile preview

Human cytomegalovirus immediate-early protein 1 (IE1) (IE1 (also IE1-72, IE72))

Target
IE1 (also IE1-72, IE72)
Molecular classification
Transcription regulator/transactivator (viral), Chromatin-associated protein; chromatin tethering via C‑terminal CTD, Innate immune antagonist (PML-NB/STAT pathway modulator), Other (viral nuclear phosphoprotein)
01

Overview

Human cytomegalovirus immediate-early protein 1 (IE1) is a 72‑kDa nuclear phosphoprotein encoded by UL123 and abundantly expressed at the onset of infection; it is a promiscuous transcriptional regulator that activates viral early genes and can autoregulate the major IE promoter, in part by antagonizing histone deacetylation through interaction with HDAC3 to enhance histone acetylation on viral chromatin. IE1 counteracts intrinsic immunity by targeting PML nuclear bodies through a conserved α‑helical core domain that binds PML’s coiled-coil, leading to PML de‑SUMOylation and release of ND10 factors (Daxx, Sp100, ATRX), which supports initiation of lytic replication; the C‑terminal acidic region also binds STAT proteins to dampen interferon signaling. The C‑terminal chromatin‑tethering domain within exon 4–derived sequences (aa 476–491) binds core histones and mitotic chromatin, ensuring efficient viral gene expression across cell division. IE1 is essential for efficient CMV replication at low multiplicity and is a key determinant of viral gene expression and immune evasion, making it a plausible antiviral target, although no approved direct IE1 inhibitors exist.

Other names
IE1IE1-72IE72Major immediate-early protein 1UL123 gene productHCMV IE1Immediate-early 1 protein
02

Mechanism of action

For agents targeting pathways modulated by IE1: HDAC inhibition increases histone acetylation to compensate for IE1’s chromatin-activating function, restoring early gene transcription in IE1-null virus

03

Biological functions

Transactivation of viral early promoters and autoregulation of the major IE promoterAntagonism of histone deacetylation by interacting with HDAC3 to promote histone acetylation and viral transcriptionDisruption/antagonism of PML nuclear body (ND10) intrinsic immunity via binding PML and inducing de-SUMOylation or sequestration of PML-NB componentsModulation of interferon/STAT signaling through C‑terminal acidic region binding STATsChromatin tethering to mitotic chromosomes via the C‑terminal chromatin-tethering domain (CTD), aiding efficient viral gene expression after mitosis
04

Disease associations

Infection (HCMV pathogenesis; required for efficient replication, especially at low MOI; implicated in reactivation biomarkers of MIE activity)
05

Safety considerations

Targeting a viral regulatory protein that interfaces extensively with host chromatin and PML/STAT pathways raises potential off-target effects if host epigenetic regulators or PML/STAT are perturbed by therapy; resistance and delivery to infected nuclei are additional challenges inferred from mechanism
06

Interacting drugs

No approved direct IE1 inhibitors are established. HDAC inhibitors (experimental context) can phenotypically rescue IE1-deficient virus replication, indicating pathway-level interaction (not direct binding drugs)
07

Biomarkers

IE1 (MIE) expression/activity is used as an indicator of CMV reactivation; major IE gene region activity is a marker for reactivation from latency

Beyond the preview

Go deeper on Human cytomegalovirus immediate-early protein 1 (IE1) (IE1 (also IE1-72, IE72)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human cytomegalovirus immediate-early protein 1 (IE1) (IE1 (also IE1-72, IE72)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call